| [1] | Jinfeng XU, Lixia QIU, Haibin YU, Yirong LIU, Jing ZHANG, Yali LIU, Wei LIN. Association of inosine triphosphate pyrophosphatase gene polymorphisms with ribavirin combined with direct-acting antiviral agent in treatment of hepatitis C patients with hemolytic anemia[J]. Journal of Clinical Hepatology, 2021, 37(10): 2320-2323. doi: 10.3969/j.issn.1001-5256.2021.10.012 |
| [2] | Xu JinFeng, Zhang XiaoHui, Liu YaLi, Zhang Jing. Influencing factors for hemolytic anemia in patients with chronic hepatitis C treated by ribavirin combined with pegylated interferon-α[J]. Journal of Clinical Hepatology, 2019, 35(2): 319-322. doi: 10.3969/j.issn.1001-5256.2019.02.015 |
| [3] | Chen XiaoYun, Zheng YanHong, Jin Yi, Yu HaiBin, Ma LiNa, Chen XinYue. Correlation between routine blood test results and antiviral effect in patients with refractory chronic hepatitis C treated with pegylated interferon-α[J]. Journal of Clinical Hepatology, 2016, 32(7): 1319-1322. doi: 10.3969/j.issn.1001-5256.2016.07.021 |
| [4] | Zhang Yu, Cao Ying, Zhang RenWen, Zhang XiaXia, Lu HaiYing, Wu ChiHong, Huo Na, Yu Min, Liu Dan, Xu XiaoYuan. Natural resistance mutations to direct- acting antiviral agents in interferon / ribavirin treatment- experienced and treatment- nave patients with chronic hepatitis C in Beijing,China[J]. Journal of Clinical Hepatology, 2016, 32(4): 711-715. doi: 10.3969/j.issn.1001-5256.2016.04.020 |
| [5] | Sun JianMin, Hu QingJun. Relevance between relapse and course of treatment in genotype 1 chronic hepatitis C patients with slow virologic response[J]. Journal of Clinical Hepatology, 2015, 31(4): 560-563. doi: 10.3969/j.issn.1001-5256.2015.04.020 |
| [6] | Lin Wei, Si JianLin, Zhang Jian, Maimaitijiang·Wubuliaishan, Hu ZhiMing, Li DongZeng, Geng Nan. Pegylated interferon alpha-2a combined with ribavirin for chronic hepatitis C: a clinical analysis of 160 patients of Uygur nationality or Han nationality[J]. Journal of Clinical Hepatology, 2015, 31(11): 1831-1836. doi: 10.3969/j.issn.1001-5256.2015.11.015 |
| [7] | Sun JianMin. Efficacy of low-dose interferon α-1b combined with ribavirin and thymosin α1 versus standard treatment for chronic hepatitis C: a comparative study [J]. Journal of Clinical Hepatology, 2015, 31(1): 107-109. doi: 10.3969/j.issn.1001-5256.2015.01.023 |
| [8] | Zhang DaLi, Zhang Min, Su HaiBin. One case of hepatitis B cirrhosis complicated by rhabdomyolysis[J]. Journal of Clinical Hepatology, 2015, 31(3): 434-435. doi: 10.3969/j.issn.1001-5256.2015.03.028 |
| [9] | Cai ShaoPing, Zhang WenJin, He WeiPing, Fan ZhenPing, Ji YingJie. Efficacy and safety of interferon plus ribavirin in elderly patients with chronic hepatitis C: report of 4 cases[J]. Journal of Clinical Hepatology, 2014, 30(1): 69-71. doi: 10.3969/j.issn.1001-5256.2014.01.019 |
| [10] | Zhang SuMei, Xie YuMei, Zhang Ying, Guo YongHong, Wei Xin, Jiang Na, Zhou Yun, Jia ZhanSheng. Potential of G-CSF supplementation to counter the neutrophil effects of standard PEG-IFNα plus ribavirin combination therapy for treating HCV-related cirrhosis [J]. Journal of Clinical Hepatology, 2013, 29(5): 348-351. |
| [11] | Zhao XiaoLing, Zhang YongGang. Clinical efficacy of ribavirin combined with different doses of interferon α- 2b in patients with chronic hepatitis C genotypes 2 and 3[J]. Journal of Clinical Hepatology, 2013, 29(10): 780-783. doi: 10.3969/j.issn.1001-5256.2013.10.014 |
| [12] | Chen XiaoYun, Zhang YongHong, Ma LiNa, Jin Yi, Yu HaiBin, Liu YaLi, Zhang XiaoDan, Guo DanDan, Xu YingXia, Zheng YanHong, Ma Bing, Chen XinYue. Clinical effect of pegylated interferon in combination with ribavirin in the retreatment of previous nonresponders or relapsers of chronic hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(12): 1291-1295. |
| [13] | Wei Xin, Xie YuMei, Chen Lin, Pan Lei, Hao ChunQiu, Wang JiuPing, Bai XueFan, Jia ZhanSheng. Antiviral therapy with pegylated interferon alpha-2a plus ribavirin in patients with HCV related cirrhosis and to establish the grading for standard therapy[J]. Journal of Clinical Hepatology, 2011, 27(1): 89-92. |
| [14] | Zhu Yan, Mao Qing, Zhang ZhangJiang, Sun Wei, Hu YaJun, Tan ChaoXia, Wang XiaoHong. Retreatment with pegylated interferon alpha-2a/2b and ribavirin in previous relapsers with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(1): 86-88. |
| [15] | Zheng YingYing, Fan XiaoHong, Wang LiFen, Tian Di, Huo Na, Lu HaiYing, Wu ChiHong, Xu XiaoYuan, Wei Lai. Efficacy and side effects of PEG-IFNα-2a plus ribavirin on elderly patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(8): 821-823. |
| [16] | Jiang XueQiang, Zou XiaoJing, Tian DeYing. Virological response of chronic hepatitis C treated with peg-interferon α-2a and Ribavirin[J]. Journal of Clinical Hepatology, 2011, 27(4): 417-419. |
| [17] | Jiao Jian, Wang JiangBin. Association between HLA-DRB and chronic hepatitis C infection and its effect on the response to interferon alpha and ribavilin therapy[J]. Journal of Clinical Hepatology, 2004, 20(6): 329-331. |
| [18] | Jiao Jian, Wang JiangBin. Study on the response to combined α-IFN, ribavilin and thymosin α1 for different types HCV infection and HCV-HBV coinfection[J]. Journal of Clinical Hepatology, 2004, 20(5): 273-274. |
DownLoad: